Targeted liposomal therapeutics

Immunoliposomes targeted to other tumor antigens were also studied by several research groups. " The immunoliposomes generally showed more significant therapeutic responses than non-targeted liposomes or the free drug. 

Sapra P, Allen TM (2002) Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 62 7190-7194... 

GosseUn, M. A. Lee, R. J. Folate receptor-targeted liposomes as vectors for therapeutic agents. Biotechnol. Annu. Rev. 2002, 8, 103-131. 

Allen, T.M., Mumbengegwi, D.R., Charrois, G.J. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and amehorates the toxicity of hposomes with var5dng drug release rates. Clin. Cancer Res. 11, 3567-3573 (2005)... 

Mayhew, E., Rustum, Y. M., and Szoka, F. (1982). Therapeutic efficacy of cytosine arabinoside trapped in liposomes, in Targeting of Drugs (G. Gregoriadis, J. Senior, and A. TTOuet, eds.). Plenum Press, New York, pp. 249-260. 

When liposomes are formed, they can be made to entrap certain compounds inside themselves, eg, drugs and isolated genes. There is interest in using liposomes to distribute drugs to certain tissues, and if components (eg, antibodies to certain cell surface molecules) could be incorporated into liposomes so that they would be targeted to specific tissues or tumors, the therapeutic impact would be considerable. DNA entrapped inside liposomes appears to be less sensitive to... 

The concept of de-PEGylation can be applied to the development of nanoparticle-based drug delivery systems. PEG is used for the modification of liposomes to increase their blood circulation time [38], However, it also prevents cellular uptake, resulting in a decrease in therapeutic efficiency thus, modifications of the liposome surface with PEG interfere with membrane fusion to the cell membrane and liposome decomposition [39]. One of the possible strategies to solve this problem is to cleave the PEG chains after the nanoparticle reaches the target site (Fig. 9). This system of de-PEGylation of liposomes is also useful in avoiding the immune... 

Figure 22.17 Antibody-liposome conjugates may be used as targeting reagents for detection or therapeutic applications. The liposome may be constructed to contain fluorescent molecules for detection purposes or bioactive agents for therapy. The antibody component targets the complex for binding to specific antigenic determinants.

Leserman, L., and Machy, P. (1987) Ligand targeting of liposomes. In Liposomes From Biophysics to Therapeutics (M.J. Ostro, ed.), pp. 157-194. Dekker, New York. 

---